Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Nursing Home Staff Closest to Patients Are Least Likely to Get COVID VaccinesLowering Medicare Age Could Help Close Racial Gaps in Health Care: StudyHow Trust in Science Can Make You Vulnerable to 'Pseudoscience'Major Medical Groups Call for Mandatory COVID Vaccination for Health WorkersU.S. to Stick With International Travel RestrictionsPatients of Color Less Likely to Get Specialist Care Than White PatientsEven at Same Hospital, Black Patients Face More Complications Than WhitesMany Patients Billed for Preventive Care That Should Be Free: StudyDrug Makers Reach $26 Billion Deal on Opioid LawsuitsCOVID Drove Biggest Drop in U.S. Life Expectancy Since World War IIU.S. Issues Toughest Travel Alert for Britain As COVID Cases There ClimbLong Distance to Care Can Mean Worse Outcomes for Young Cancer PatientsCanada May Open Borders to Fully Vaccinated Americans by Mid-AugustWhy Many Black & Hispanic Americans Distrust COVID Vaccines$345 Million Settlement Proposed in EpiPen LawsuitsAHA News: How Healthy Is Your Neighborhood? Where You Live Can Greatly Affect Heart, Brain HealthExtreme Heat Hits Poorer Neighborhoods HarderFive Neutrogena and Aveeno Spray Sunscreens Recalled Due to BenzeneMany States Move to Ban Vaccine Mandates, Passports in Public SchoolsWHO Calls for Global Registry of Human Genome EditingMost Cancer Screenings Make Big Rebound After Pandemic DeclineBlack Churches Could Be Key to Boosting Vaccination RatesFDA Head Asks for Investigation Into Alzheimer's Drug ApprovalWhy Even the Healthy Need a Primary Care DoctorClimate Change Already Causes 5 Million Extra Deaths Per YearIs Medicare Overspending? Costco Prices Much Less for Generic DrugsLanguage Barriers Keep 25 million in U.S. From Good Health CareState Lotteries Don't Boost COVID Vaccination Numbers: StudyBlood Shortages Causing Surgery Delays Across U.S.Walmart to Offer Low-Priced InsulinCould Home Test for Colon Cancer Mean a Big Medical Bill to Come?Juul to Pay $40 Million in N.C. Case Over Vaping's Harm to TeensHospitals: One Reason COVID Is More Lethal for Black AmericansU.S. Supreme Court Strikes Down Challenge to Affordable Care ActHow Secure Is Your Health or Fitness App?Doctors May Be Overprescribing Opioids After SurgeriesMost Editors at Leading Medical Journals Are White, Study FindsAHA News: Why Everyone Should Care About Health Disparities – And What to Do About ThemUS to Send 500 Million COVID Vaccine Doses to Countries Desperate for ShotsThink You Can Skip That Annual Physical?  Think AgainYour Doctor Appointments Might Look Different Post-PandemicU.S. Blood Supply Is Safe From Coronavirus, Study FindsThink You Can Spot Fake News? Many Can'tTelehealth Is Growing in Use, Acceptance Among Americans: PollAHA News: Deep Disparities Persist in Who Gets Exposed to Secondhand SmokeMany Pre-Surgery Tests Are Useless, So Why Are Hospitals Still Using Them?U.S. Officials Say 50% of American Adults Are Now Fully VaccinatedMore Pot-Linked Poisoning Cases as Edibles' Popularity BoomsU.S. Issues Tough Travel Warnings for Japan Ahead of OlympicsScience Studies Most Likely to Be Wrong Are the Most Widely Read
Questions and AnswersVideosLinksBook Reviews
Related Topics

Health Insurance
Healthcare

$345 Million Settlement Proposed in EpiPen Lawsuits

HealthDay News
by Robert Preidt
Updated: Jul 16th 2021

new article illustration

FRIDAY, July 16, 2021 (HealthDay News) -- Pfizer Inc. has agreed to pay $345 million in a proposed settlement to resolve lawsuits over steep EpiPen price increases.

EpiPens are auto-injectable devices that deliver the drug epinephrine for emergency treatment of a life-threatening allergic reaction called anaphylaxis.

In 2016, a number of class-action lawsuits were filed against Pfizer and its subsidiaries Meridian Medical Technologies Inc. and King Pharmaceuticals, alleging they engaged in anticompetitive conduct related to EpiPen, the Associated Press reported.

Another company that is a defendant in the litigation is Mylan, which owns the EpiPen brand, even though the devices are made by Pfizer.

Mylan acquired the right to market and distribute the devices in 2007, when an EpiPen package cost about $100. Now, it costs more than $650 without pharmacy coupons or manufacturer discounts, the AP reported.

Court documents filed Thursday in federal court in Kansas City, Kansas, show that Pfizer and its two subsidiaries asked the court to give preliminary approval to the settlement, according to Kansas City's NPR station KCUR-FM.

Three weeks ago, most of the claims against Mylan were dismissed, but the judge allowed antitrust claims against the company to proceed to trial, scheduled to start on Sept. 7, the AP reported.

Rex Sharp, a lawyer for the plaintiffs, said his clients were pleased that Pfizer had agreed to the settlement, noting it would still need the court's approval, the AP reported

In an email to KCUR-FM, a Pfizer spokesperson denied any wrongdoing by the company and said the settlement was sought to avoid "the distraction of continued litigation and focus on breakthroughs that change patients' lives."

More information

The National Institute of Allergy and Infectious Diseases has more on food allergies.


SOURCE: Associated Press




Facebook

Amazon Smile

 

Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.

 


powered by centersite dot net